154 related articles for article (PubMed ID: 20032811)
1. MT1G hypermethylation: a potential prognostic marker for hepatoblastoma.
Sakamoto LH; DE Camargo B; Cajaiba M; Soares FA; Vettore AL
Pediatr Res; 2010 Apr; 67(4):387-93. PubMed ID: 20032811
[TBL] [Abstract][Full Text] [Related]
2. MT1G hypermethylation is associated with higher tumor stage in prostate cancer.
Henrique R; Jerónimo C; Hoque MO; Nomoto S; Carvalho AL; Costa VL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1274-8. PubMed ID: 15894685
[TBL] [Abstract][Full Text] [Related]
3. Hypermethylation of the p16 gene and lack of p16 expression in hepatoblastoma.
Shim YH; Park HJ; Choi MS; Kim JS; Kim H; Kim JJ; Jang JJ; Yu E
Mod Pathol; 2003 May; 16(5):430-6. PubMed ID: 12748249
[TBL] [Abstract][Full Text] [Related]
4. Hepatoblastomas exhibit marked
Rivas MP; Aguiar TFM; Maschietto M; Lemes RB; Caires-Júnior LC; Goulart E; Telles-Silva KA; Novak E; Cristofani LM; Odone V; Cypriano M; de Toledo SRC; Carraro DM; Escobar MQ; Lee H; Johnston M; da Costa CML; da Cunha IW; Tasic L; Pearson PL; Rosenberg C; Timchenko N; Krepischi ACV
Tumour Biol; 2020 Dec; 42(12):1010428320977124. PubMed ID: 33256542
[TBL] [Abstract][Full Text] [Related]
5. The methylation status of RASSF1A promoter predicts responsiveness to chemotherapy and eventual cure in hepatoblastoma patients.
Honda S; Haruta M; Sugawara W; Sasaki F; Ohira M; Matsunaga T; Yamaoka H; Horie H; Ohnuma N; Nakagawara A; Hiyama E; Todo S; Kaneko Y
Int J Cancer; 2008 Sep; 123(5):1117-25. PubMed ID: 18537155
[TBL] [Abstract][Full Text] [Related]
6. GSTP1 hypermethylation is associated with reduced protein expression, aggressive disease and prognosis in neuroblastoma.
Gumy-Pause F; Pardo B; Khoshbeen-Boudal M; Ansari M; Gayet-Ageron A; Sappino AP; Attiyeh EF; Ozsahin H
Genes Chromosomes Cancer; 2012 Feb; 51(2):174-85. PubMed ID: 22045684
[TBL] [Abstract][Full Text] [Related]
7. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
[TBL] [Abstract][Full Text] [Related]
8. [Hypermethylation as a potential prognostic factor and a clue to a better understanding of the molecular pathogenesis of medulloblastoma--results of a genomewide methylation scan].
Frühwald MC; O'Dorisio MS; Smith L; Dai Z; Wright FA; Paulus W; Jürgens H; Plass C
Klin Padiatr; 2001; 213(4):197-203. PubMed ID: 11528554
[TBL] [Abstract][Full Text] [Related]
9. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
10. RASSF1A methylation indicates a poor prognosis in hepatoblastoma patients.
Honda S; Miyagi H; Suzuki H; Minato M; Haruta M; Kaneko Y; Hatanaka KC; Hiyama E; Kamijo T; Okada T; Taketomi A
Pediatr Surg Int; 2013 Nov; 29(11):1147-52. PubMed ID: 23989600
[TBL] [Abstract][Full Text] [Related]
11. Promoter hypermethylation profile of kidney cancer.
Dulaimi E; Ibanez de Caceres I; Uzzo RG; Al-Saleem T; Greenberg RE; Polascik TJ; Babb JS; Grizzle WE; Cairns P
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3972-9. PubMed ID: 15217927
[TBL] [Abstract][Full Text] [Related]
12. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.
Hoque MO; Begum S; Topaloglu O; Chatterjee A; Rosenbaum E; Van Criekinge W; Westra WH; Schoenberg M; Zahurak M; Goodman SN; Sidransky D
J Natl Cancer Inst; 2006 Jul; 98(14):996-1004. PubMed ID: 16849682
[TBL] [Abstract][Full Text] [Related]
13. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer.
Hoque MO; Begum S; Topaloglu O; Jeronimo C; Mambo E; Westra WH; Califano JA; Sidransky D
Cancer Res; 2004 Aug; 64(15):5511-7. PubMed ID: 15289362
[TBL] [Abstract][Full Text] [Related]
14. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only.
De Schutter H; Geeraerts H; Verbeken E; Nuyts S
Oncol Rep; 2009 Feb; 21(2):507-13. PubMed ID: 19148529
[TBL] [Abstract][Full Text] [Related]
15. Amplification and overexpression of the IGF2 regulator PLAG1 in hepatoblastoma.
Zatkova A; Rouillard JM; Hartmann W; Lamb BJ; Kuick R; Eckart M; von Schweinitz D; Koch A; Fonatsch C; Pietsch T; Hanash SM; Wimmer K
Genes Chromosomes Cancer; 2004 Feb; 39(2):126-37. PubMed ID: 14695992
[TBL] [Abstract][Full Text] [Related]
16. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
[TBL] [Abstract][Full Text] [Related]
17. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects.
Hoque MO; Topaloglu O; Begum S; Henrique R; Rosenbaum E; Van Criekinge W; Westra WH; Sidransky D
J Clin Oncol; 2005 Sep; 23(27):6569-75. PubMed ID: 16170165
[TBL] [Abstract][Full Text] [Related]
18. Promoter hypermethylation of the p16 gene is associated with poor prognosis in recurrent early-stage hepatocellular carcinoma.
Ko E; Kim Y; Kim SJ; Joh JW; Song S; Park CK; Park J; Kim DH
Cancer Epidemiol Biomarkers Prev; 2008 Sep; 17(9):2260-7. PubMed ID: 18723830
[TBL] [Abstract][Full Text] [Related]
19. High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma.
Yeo W; Wong N; Wong WL; Lai PB; Zhong S; Johnson PJ
Liver Int; 2005 Apr; 25(2):266-72. PubMed ID: 15780049
[TBL] [Abstract][Full Text] [Related]
20. Blocking the hedgehog pathway inhibits hepatoblastoma growth.
Eichenmüller M; Gruner I; Hagl B; Häberle B; Müller-Höcker J; von Schweinitz D; Kappler R
Hepatology; 2009 Feb; 49(2):482-90. PubMed ID: 19177589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]